Discontinuation of Biological Treatments in Inflammatory Bowel Disease

Shomron Ben-Horin*, Ren Mao, Yun Qiu, Minhu Chen

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Despite the proven efficacy of biological drugs for inflammatory bowel disease, these therapies are costly and do carry some risks, providing incentive for exploring strategies to discontinue therapy in patients with prolonged remission. We presently review multiple cohort studies indicating the overall risk of relapse after stopping an anti-tumor necrosis factor (TNF) in inflammatory bowel disease patients is roughly 40% at 12 months after therapy cessation. Despite methodological differences across studies, it appears that patients without deep remission (ie, patients with endoscopic or biomarker evidence of inflammation) are at increased risk of relapse after stopping anti-TNF, as are those with high-adequate levels of anti-TNF before stopping. In patients who relapse after anti-TNF cessation, retreatment with the same biological seems to reinduce clinical response in most patients. Immunological reasons responsible for this high success rate for retreatment are elucidated, but resorting to retreatment also implies a small but finite risk of a severe flare leading to surgery, which should be borne in mind. Thus, stopping attempts should probably be reserved for patients with low risk for severe outcome should a relapse occur. Proactive endoscopic monitoring after drug cessation is imperative to reduce these risks. The recently introduced concept of treatment-cycles is discussed, along with a pragmatic algorithm of decision tree for therapy discontinuation in the selected appropriate patients.

Original languageEnglish
Pages (from-to)6-12
Number of pages7
JournalJournal of Clinical Gastroenterology
Issue number1
StatePublished - 2017


FundersFunder number
European Union’s Horizon 2020 research and innovation program633168, PHC-13-2014
Sheba Medical Center


    • anti-TNF antibodies
    • inflammatory bowel disease
    • therapy


    Dive into the research topics of 'Discontinuation of Biological Treatments in Inflammatory Bowel Disease'. Together they form a unique fingerprint.

    Cite this